nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—TEK—sarcoma	0.173	0.323	CbGaD
Ponatinib—PDGFRA—sarcoma	0.109	0.203	CbGaD
Ponatinib—SRC—sarcoma	0.0901	0.168	CbGaD
Ponatinib—KDR—sarcoma	0.0847	0.158	CbGaD
Ponatinib—KIT—sarcoma	0.0799	0.149	CbGaD
Ponatinib—ABCB11—Vincristine—sarcoma	0.0295	0.146	CbGbCtD
Ponatinib—ABCG2—Dactinomycin—sarcoma	0.0228	0.113	CbGbCtD
Ponatinib—ABCG2—Mitoxantrone—sarcoma	0.0204	0.101	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—sarcoma	0.0185	0.0912	CbGbCtD
Ponatinib—ABCG2—Vincristine—sarcoma	0.014	0.0694	CbGbCtD
Ponatinib—ABCG2—Etoposide—sarcoma	0.0129	0.0636	CbGbCtD
Ponatinib—CYP3A4—Thiotepa—sarcoma	0.0102	0.0506	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—sarcoma	0.00877	0.0433	CbGbCtD
Ponatinib—ABCB1—Dactinomycin—sarcoma	0.00822	0.0406	CbGbCtD
Ponatinib—CYP3A5—Vincristine—sarcoma	0.00778	0.0384	CbGbCtD
Ponatinib—ABCB1—Mitoxantrone—sarcoma	0.00736	0.0363	CbGbCtD
Ponatinib—CYP3A5—Etoposide—sarcoma	0.00713	0.0352	CbGbCtD
Ponatinib—CYP2C8—Etoposide—sarcoma	0.00685	0.0339	CbGbCtD
Ponatinib—FGFR3—epiphyseal plate—sarcoma	0.00541	0.0882	CbGeAlD
Ponatinib—ABCB1—Vincristine—sarcoma	0.00506	0.025	CbGbCtD
Ponatinib—ABCB1—Etoposide—sarcoma	0.00464	0.0229	CbGbCtD
Ponatinib—CYP3A4—Mitoxantrone—sarcoma	0.00441	0.0218	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—sarcoma	0.00316	0.0156	CbGbCtD
Ponatinib—CYP3A4—Vincristine—sarcoma	0.00303	0.015	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—sarcoma	0.00298	0.0147	CbGbCtD
Ponatinib—CYP3A4—Etoposide—sarcoma	0.00278	0.0137	CbGbCtD
Ponatinib—FGFR3—skull—sarcoma	0.00226	0.0369	CbGeAlD
Ponatinib—FGFR3—cartilage tissue—sarcoma	0.00193	0.0315	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—sarcoma	0.0019	0.00936	CbGbCtD
Ponatinib—FGFR3—appendage—sarcoma	0.00168	0.0274	CbGeAlD
Ponatinib—SRC—periosteum—sarcoma	0.00154	0.025	CbGeAlD
Ponatinib—FGFR2—skull—sarcoma	0.00148	0.0241	CbGeAlD
Ponatinib—FGFR4—mammary gland—sarcoma	0.0012	0.0195	CbGeAlD
Ponatinib—KDR—umbilical vein—sarcoma	0.0011	0.0179	CbGeAlD
Ponatinib—Nilotinib—TEK—sarcoma	0.00103	0.239	CrCbGaD
Ponatinib—KDR—hindlimb—sarcoma	0.00101	0.0164	CbGeAlD
Ponatinib—FGFR4—Podofilox—Etoposide—sarcoma	0.000983	0.416	CbGdCrCtD
Ponatinib—KDR—appendage—sarcoma	0.000863	0.0141	CbGeAlD
Ponatinib—FGFR4—embryo—sarcoma	0.000819	0.0133	CbGeAlD
Ponatinib—FGFR4—hematopoietic system—sarcoma	0.000731	0.0119	CbGeAlD
Ponatinib—BCR—mammary gland—sarcoma	0.000708	0.0115	CbGeAlD
Ponatinib—FGFR4—connective tissue—sarcoma	0.000704	0.0115	CbGeAlD
Ponatinib—FGFR4—Vinblastine—Vincristine—sarcoma	0.000677	0.286	CbGdCrCtD
Ponatinib—Nilotinib—PDGFRB—sarcoma	0.000667	0.154	CrCbGaD
Ponatinib—Nilotinib—PDGFRA—sarcoma	0.00065	0.15	CrCbGaD
Ponatinib—TEK—endothelium—sarcoma	0.000637	0.0104	CbGeAlD
Ponatinib—SRC—endothelium—sarcoma	0.000566	0.00923	CbGeAlD
Ponatinib—RET—mammary gland—sarcoma	0.000564	0.00919	CbGeAlD
Ponatinib—FGFR3—embryo—sarcoma	0.000559	0.0091	CbGeAlD
Ponatinib—Imatinib—PDGFRB—sarcoma	0.000556	0.129	CrCbGaD
Ponatinib—Imatinib—PDGFRA—sarcoma	0.000542	0.125	CrCbGaD
Ponatinib—FGFR2—mammary gland—sarcoma	0.000536	0.00873	CbGeAlD
Ponatinib—KDR—endothelium—sarcoma	0.000521	0.00849	CbGeAlD
Ponatinib—TEK—mammary gland—sarcoma	0.000514	0.00837	CbGeAlD
Ponatinib—BCR—myometrium—sarcoma	0.000503	0.00819	CbGeAlD
Ponatinib—LYN—hematopoietic system—sarcoma	0.000501	0.00817	CbGeAlD
Ponatinib—FGFR3—hematopoietic system—sarcoma	0.000499	0.00813	CbGeAlD
Ponatinib—LYN—connective tissue—sarcoma	0.000483	0.00786	CbGeAlD
Ponatinib—FGFR3—connective tissue—sarcoma	0.00048	0.00782	CbGeAlD
Ponatinib—Nilotinib—KIT—sarcoma	0.000477	0.11	CrCbGaD
Ponatinib—PDGFRA—mammary gland—sarcoma	0.000465	0.00758	CbGeAlD
Ponatinib—KIT—endothelium—sarcoma	0.000462	0.00752	CbGeAlD
Ponatinib—BCR—seminal vesicle—sarcoma	0.000454	0.0074	CbGeAlD
Ponatinib—FGFR1—myometrium—sarcoma	0.000447	0.00729	CbGeAlD
Ponatinib—FGFR3—skin of body—sarcoma	0.000434	0.00706	CbGeAlD
Ponatinib—BCR—hematopoietic system—sarcoma	0.000432	0.00703	CbGeAlD
Ponatinib—FLT3—hematopoietic system—sarcoma	0.000429	0.00698	CbGeAlD
Ponatinib—KDR—mammary gland—sarcoma	0.00042	0.00684	CbGeAlD
Ponatinib—FLT3—connective tissue—sarcoma	0.000413	0.00672	CbGeAlD
Ponatinib—FGFR4—testis—sarcoma	0.000401	0.00653	CbGeAlD
Ponatinib—Imatinib—KIT—sarcoma	0.000398	0.092	CrCbGaD
Ponatinib—RET—embryo—sarcoma	0.000385	0.00627	CbGeAlD
Ponatinib—FGFR4—liver—sarcoma	0.000379	0.00617	CbGeAlD
Ponatinib—KIT—mammary gland—sarcoma	0.000372	0.00606	CbGeAlD
Ponatinib—FGFR2—embryo—sarcoma	0.000366	0.00596	CbGeAlD
Ponatinib—LYN—lymphoid tissue—sarcoma	0.000353	0.00575	CbGeAlD
Ponatinib—TEK—embryo—sarcoma	0.000351	0.00571	CbGeAlD
Ponatinib—RET—hematopoietic system—sarcoma	0.000344	0.0056	CbGeAlD
Ponatinib—RET—connective tissue—sarcoma	0.000331	0.00539	CbGeAlD
Ponatinib—BCR—cardiac atrium—sarcoma	0.000328	0.00534	CbGeAlD
Ponatinib—FGFR2—hematopoietic system—sarcoma	0.000326	0.00532	CbGeAlD
Ponatinib—BCR—uterus—sarcoma	0.000326	0.00531	CbGeAlD
Ponatinib—ABL1—mammary gland—sarcoma	0.000324	0.00528	CbGeAlD
Ponatinib—PDGFRA—embryo—sarcoma	0.000318	0.00518	CbGeAlD
Ponatinib—FGFR2—connective tissue—sarcoma	0.000314	0.00512	CbGeAlD
Ponatinib—TEK—hematopoietic system—sarcoma	0.000313	0.0051	CbGeAlD
Ponatinib—SRC—embryo—sarcoma	0.000312	0.00508	CbGeAlD
Ponatinib—BCR—lymphoid tissue—sarcoma	0.000304	0.00495	CbGeAlD
Ponatinib—FLT3—lymphoid tissue—sarcoma	0.000302	0.00491	CbGeAlD
Ponatinib—TEK—connective tissue—sarcoma	0.000301	0.00491	CbGeAlD
Ponatinib—KDR—myometrium—sarcoma	0.000298	0.00485	CbGeAlD
Ponatinib—FGFR1—cardiac atrium—sarcoma	0.000292	0.00475	CbGeAlD
Ponatinib—FGFR4—lymph node—sarcoma	0.00029	0.00473	CbGeAlD
Ponatinib—FGFR1—uterus—sarcoma	0.00029	0.00473	CbGeAlD
Ponatinib—FGFR2—smooth muscle tissue—sarcoma	0.000288	0.00468	CbGeAlD
Ponatinib—KDR—embryo—sarcoma	0.000287	0.00467	CbGeAlD
Ponatinib—BCR—tendon—sarcoma	0.000286	0.00465	CbGeAlD
Ponatinib—FGFR2—skin of body—sarcoma	0.000284	0.00462	CbGeAlD
Ponatinib—PDGFRA—hematopoietic system—sarcoma	0.000284	0.00462	CbGeAlD
Ponatinib—SRC—hematopoietic system—sarcoma	0.000278	0.00453	CbGeAlD
Ponatinib—BCR—bone marrow—sarcoma	0.000277	0.00451	CbGeAlD
Ponatinib—TEK—smooth muscle tissue—sarcoma	0.000276	0.00449	CbGeAlD
Ponatinib—FLT3—bone marrow—sarcoma	0.000275	0.00448	CbGeAlD
Ponatinib—FGFR3—testis—sarcoma	0.000273	0.00445	CbGeAlD
Ponatinib—PDGFRA—connective tissue—sarcoma	0.000273	0.00445	CbGeAlD
Ponatinib—KDR—seminal vesicle—sarcoma	0.000269	0.00439	CbGeAlD
Ponatinib—SRC—connective tissue—sarcoma	0.000268	0.00436	CbGeAlD
Ponatinib—KIT—myometrium—sarcoma	0.000264	0.0043	CbGeAlD
Ponatinib—LYN—liver—sarcoma	0.00026	0.00423	CbGeAlD
Ponatinib—LCK—uterus—sarcoma	0.00026	0.00423	CbGeAlD
Ponatinib—FGFR3—liver—sarcoma	0.000258	0.00421	CbGeAlD
Ponatinib—KDR—hematopoietic system—sarcoma	0.000256	0.00417	CbGeAlD
Ponatinib—FGFR1—tendon—sarcoma	0.000254	0.00414	CbGeAlD
Ponatinib—KIT—embryo—sarcoma	0.000254	0.00414	CbGeAlD
Ponatinib—PDGFRA—smooth muscle tissue—sarcoma	0.00025	0.00407	CbGeAlD
Ponatinib—FGFR2—uterus—sarcoma	0.000247	0.00402	CbGeAlD
Ponatinib—KDR—connective tissue—sarcoma	0.000246	0.00401	CbGeAlD
Ponatinib—SRC—smooth muscle tissue—sarcoma	0.000245	0.00399	CbGeAlD
Ponatinib—RET—lymphoid tissue—sarcoma	0.000242	0.00394	CbGeAlD
Ponatinib—SRC—skin of body—sarcoma	0.000242	0.00394	CbGeAlD
Ponatinib—KIT—seminal vesicle—sarcoma	0.000239	0.00389	CbGeAlD
Ponatinib—TEK—cardiac atrium—sarcoma	0.000238	0.00387	CbGeAlD
Ponatinib—BCR—testis—sarcoma	0.000236	0.00385	CbGeAlD
Ponatinib—TEK—uterus—sarcoma	0.000236	0.00385	CbGeAlD
Ponatinib—FLT3—testis—sarcoma	0.000235	0.00383	CbGeAlD
Ponatinib—ABL1—myometrium—sarcoma	0.00023	0.00374	CbGeAlD
Ponatinib—RET—tendon—sarcoma	0.000227	0.0037	CbGeAlD
Ponatinib—KIT—hematopoietic system—sarcoma	0.000227	0.00369	CbGeAlD
Ponatinib—KDR—smooth muscle tissue—sarcoma	0.000225	0.00367	CbGeAlD
Ponatinib—BCR—liver—sarcoma	0.000224	0.00364	CbGeAlD
Ponatinib—FLT3—liver—sarcoma	0.000222	0.00362	CbGeAlD
Ponatinib—ABL1—embryo—sarcoma	0.000221	0.0036	CbGeAlD
Ponatinib—TEK—lymphoid tissue—sarcoma	0.00022	0.00359	CbGeAlD
Ponatinib—LCK—bone marrow—sarcoma	0.00022	0.00359	CbGeAlD
Ponatinib—KIT—connective tissue—sarcoma	0.000218	0.00356	CbGeAlD
Ponatinib—PDGFRA—uterus—sarcoma	0.000214	0.00349	CbGeAlD
Ponatinib—SRC—cardiac atrium—sarcoma	0.000211	0.00344	CbGeAlD
Ponatinib—FGFR1—testis—sarcoma	0.00021	0.00343	CbGeAlD
Ponatinib—CYP2C8—mammary gland—sarcoma	0.00021	0.00342	CbGeAlD
Ponatinib—ABL1—seminal vesicle—sarcoma	0.000208	0.00338	CbGeAlD
Ponatinib—TEK—tendon—sarcoma	0.000207	0.00337	CbGeAlD
Ponatinib—KIT—smooth muscle tissue—sarcoma	0.0002	0.00325	CbGeAlD
Ponatinib—PDGFRA—lymphoid tissue—sarcoma	0.0002	0.00325	CbGeAlD
Ponatinib—FGFR1—liver—sarcoma	0.000199	0.00324	CbGeAlD
Ponatinib—ABL1—hematopoietic system—sarcoma	0.000197	0.00322	CbGeAlD
Ponatinib—KIT—skin of body—sarcoma	0.000197	0.00321	CbGeAlD
Ponatinib—SRC—lymphoid tissue—sarcoma	0.000196	0.00319	CbGeAlD
Ponatinib—KDR—cardiac atrium—sarcoma	0.000194	0.00316	CbGeAlD
Ponatinib—KDR—uterus—sarcoma	0.000193	0.00315	CbGeAlD
Ponatinib—ABL1—connective tissue—sarcoma	0.00019	0.0031	CbGeAlD
Ponatinib—LCK—testis—sarcoma	0.000188	0.00307	CbGeAlD
Ponatinib—RET—testis—sarcoma	0.000188	0.00307	CbGeAlD
Ponatinib—PDGFRA—tendon—sarcoma	0.000188	0.00306	CbGeAlD
Ponatinib—ABCB11—testis—sarcoma	0.000184	0.003	CbGeAlD
Ponatinib—KDR—lymphoid tissue—sarcoma	0.00018	0.00293	CbGeAlD
Ponatinib—FGFR2—testis—sarcoma	0.000179	0.00291	CbGeAlD
Ponatinib—LCK—liver—sarcoma	0.000178	0.0029	CbGeAlD
Ponatinib—ABCB11—liver—sarcoma	0.000174	0.00283	CbGeAlD
Ponatinib—ABL1—smooth muscle tissue—sarcoma	0.000174	0.00283	CbGeAlD
Ponatinib—ABL1—skin of body—sarcoma	0.000172	0.0028	CbGeAlD
Ponatinib—TEK—testis—sarcoma	0.000172	0.00279	CbGeAlD
Ponatinib—BCR—lymph node—sarcoma	0.000171	0.00279	CbGeAlD
Ponatinib—KIT—uterus—sarcoma	0.000171	0.00279	CbGeAlD
Ponatinib—FLT3—lymph node—sarcoma	0.00017	0.00277	CbGeAlD
Ponatinib—KDR—tendon—sarcoma	0.000169	0.00276	CbGeAlD
Ponatinib—FGFR2—liver—sarcoma	0.000169	0.00276	CbGeAlD
Ponatinib—KDR—bone marrow—sarcoma	0.000164	0.00267	CbGeAlD
Ponatinib—TEK—liver—sarcoma	0.000162	0.00264	CbGeAlD
Ponatinib—KIT—lymphoid tissue—sarcoma	0.00016	0.0026	CbGeAlD
Ponatinib—PDGFRA—testis—sarcoma	0.000155	0.00253	CbGeAlD
Ponatinib—FGFR1—lymph node—sarcoma	0.000153	0.00248	CbGeAlD
Ponatinib—SRC—testis—sarcoma	0.000152	0.00248	CbGeAlD
Ponatinib—ABL1—cardiac atrium—sarcoma	0.00015	0.00244	CbGeAlD
Ponatinib—ABL1—uterus—sarcoma	0.000149	0.00243	CbGeAlD
Ponatinib—PDGFRA—liver—sarcoma	0.000147	0.00239	CbGeAlD
Ponatinib—KIT—bone marrow—sarcoma	0.000145	0.00237	CbGeAlD
Ponatinib—ABCG2—myometrium—sarcoma	0.000145	0.00236	CbGeAlD
Ponatinib—SRC—liver—sarcoma	0.000144	0.00235	CbGeAlD
Ponatinib—KDR—testis—sarcoma	0.00014	0.00228	CbGeAlD
Ponatinib—ABL1—lymphoid tissue—sarcoma	0.000139	0.00226	CbGeAlD
Ponatinib—LCK—lymph node—sarcoma	0.000136	0.00222	CbGeAlD
Ponatinib—RET—lymph node—sarcoma	0.000136	0.00222	CbGeAlD
Ponatinib—KDR—liver—sarcoma	0.000133	0.00216	CbGeAlD
Ponatinib—ABCG2—seminal vesicle—sarcoma	0.000131	0.00213	CbGeAlD
Ponatinib—ABL1—tendon—sarcoma	0.000131	0.00213	CbGeAlD
Ponatinib—CYP2C8—hematopoietic system—sarcoma	0.000128	0.00209	CbGeAlD
Ponatinib—ABL1—bone marrow—sarcoma	0.000127	0.00206	CbGeAlD
Ponatinib—TEK—lymph node—sarcoma	0.000124	0.00203	CbGeAlD
Ponatinib—KIT—testis—sarcoma	0.000124	0.00202	CbGeAlD
Ponatinib—ABL1—Idarubicin—Epirubicin—sarcoma	0.000122	0.0517	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—sarcoma	0.000122	0.0517	CbGdCrCtD
Ponatinib—ABL1—Doxorubicin—Epirubicin—sarcoma	0.000122	0.0517	CbGdCrCtD
Ponatinib—KIT—liver—sarcoma	0.000117	0.00191	CbGeAlD
Ponatinib—CYP3A5—hematopoietic system—sarcoma	0.000116	0.00188	CbGeAlD
Ponatinib—ABL1—Epirubicin—Doxorubicin—sarcoma	0.000113	0.0478	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—sarcoma	0.000113	0.0478	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—sarcoma	0.000113	0.0478	CbGdCrCtD
Ponatinib—PDGFRA—lymph node—sarcoma	0.000113	0.00184	CbGeAlD
Ponatinib—SRC—lymph node—sarcoma	0.00011	0.0018	CbGeAlD
Ponatinib—ABL1—testis—sarcoma	0.000108	0.00176	CbGeAlD
Ponatinib—ABL1—liver—sarcoma	0.000102	0.00167	CbGeAlD
Ponatinib—KDR—lymph node—sarcoma	0.000102	0.00166	CbGeAlD
Ponatinib—ABCG2—uterus—sarcoma	9.4e-05	0.00153	CbGeAlD
Ponatinib—KIT—lymph node—sarcoma	9.01e-05	0.00147	CbGeAlD
Ponatinib—CYP3A4—hematopoietic system—sarcoma	8.67e-05	0.00141	CbGeAlD
Ponatinib—CYP2D6—hematopoietic system—sarcoma	8.53e-05	0.00139	CbGeAlD
Ponatinib—ABCG2—bone marrow—sarcoma	7.98e-05	0.0013	CbGeAlD
Ponatinib—ABL1—lymph node—sarcoma	7.84e-05	0.00128	CbGeAlD
Ponatinib—Face oedema—Epirubicin—sarcoma	7.76e-05	0.000981	CcSEcCtD
Ponatinib—Body temperature increased—Thiotepa—sarcoma	7.76e-05	0.00098	CcSEcCtD
Ponatinib—Abdominal pain—Thiotepa—sarcoma	7.76e-05	0.00098	CcSEcCtD
Ponatinib—Leukopenia—Etoposide—sarcoma	7.73e-05	0.000977	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Mitoxantrone—sarcoma	7.72e-05	0.000976	CcSEcCtD
Ponatinib—Body temperature increased—Dactinomycin—sarcoma	7.7e-05	0.000973	CcSEcCtD
Ponatinib—Abdominal pain—Dactinomycin—sarcoma	7.7e-05	0.000973	CcSEcCtD
Ponatinib—Cardiac failure—Doxorubicin—sarcoma	7.62e-05	0.000963	CcSEcCtD
Ponatinib—Paraesthesia—Mitoxantrone—sarcoma	7.61e-05	0.000962	CcSEcCtD
Ponatinib—Lethargy—Doxorubicin—sarcoma	7.59e-05	0.000959	CcSEcCtD
Ponatinib—Cerebrovascular accident—Doxorubicin—sarcoma	7.59e-05	0.000959	CcSEcCtD
Ponatinib—Decreased appetite—Vincristine—sarcoma	7.57e-05	0.000956	CcSEcCtD
Ponatinib—Dyspnoea—Mitoxantrone—sarcoma	7.56e-05	0.000955	CcSEcCtD
Ponatinib—Cough—Etoposide—sarcoma	7.54e-05	0.000953	CcSEcCtD
Ponatinib—Blood creatinine increased—Epirubicin—sarcoma	7.53e-05	0.000952	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Vincristine—sarcoma	7.51e-05	0.000949	CcSEcCtD
Ponatinib—Fatigue—Vincristine—sarcoma	7.5e-05	0.000948	CcSEcCtD
Ponatinib—Dehydration—Epirubicin—sarcoma	7.48e-05	0.000945	CcSEcCtD
Ponatinib—Hyponatraemia—Doxorubicin—sarcoma	7.47e-05	0.000944	CcSEcCtD
Ponatinib—Dyspepsia—Mitoxantrone—sarcoma	7.46e-05	0.000943	CcSEcCtD
Ponatinib—Hypertension—Etoposide—sarcoma	7.46e-05	0.000942	CcSEcCtD
Ponatinib—Pain—Vincristine—sarcoma	7.44e-05	0.00094	CcSEcCtD
Ponatinib—Constipation—Vincristine—sarcoma	7.44e-05	0.00094	CcSEcCtD
Ponatinib—Pain in extremity—Doxorubicin—sarcoma	7.44e-05	0.00094	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	7.44e-05	0.00094	CcSEcCtD
Ponatinib—Dry skin—Epirubicin—sarcoma	7.37e-05	0.000931	CcSEcCtD
Ponatinib—Decreased appetite—Mitoxantrone—sarcoma	7.37e-05	0.000931	CcSEcCtD
Ponatinib—Migraine—Doxorubicin—sarcoma	7.32e-05	0.000925	CcSEcCtD
Ponatinib—Hypokalaemia—Epirubicin—sarcoma	7.32e-05	0.000925	CcSEcCtD
Ponatinib—Fatigue—Mitoxantrone—sarcoma	7.31e-05	0.000923	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	7.3e-05	0.000923	CcSEcCtD
Ponatinib—Breast disorder—Epirubicin—sarcoma	7.27e-05	0.000918	CcSEcCtD
Ponatinib—Pain—Mitoxantrone—sarcoma	7.25e-05	0.000916	CcSEcCtD
Ponatinib—Constipation—Mitoxantrone—sarcoma	7.25e-05	0.000916	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Epirubicin—sarcoma	7.24e-05	0.000915	CcSEcCtD
Ponatinib—Nasopharyngitis—Epirubicin—sarcoma	7.19e-05	0.000909	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—sarcoma	7.18e-05	0.000908	CcSEcCtD
Ponatinib—ABCB1—myometrium—sarcoma	7.15e-05	0.00116	CbGeAlD
Ponatinib—Gastrointestinal pain—Vincristine—sarcoma	7.12e-05	0.000899	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Epirubicin—sarcoma	7.09e-05	0.000896	CcSEcCtD
Ponatinib—Asthenia—Thiotepa—sarcoma	7.04e-05	0.00089	CcSEcCtD
Ponatinib—CYP2C8—testis—sarcoma	7.01e-05	0.00114	CbGeAlD
Ponatinib—Infection—Etoposide—sarcoma	7.01e-05	0.000885	CcSEcCtD
Ponatinib—Abdominal distension—Epirubicin—sarcoma	7e-05	0.000884	CcSEcCtD
Ponatinib—Asthenia—Dactinomycin—sarcoma	6.99e-05	0.000883	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—sarcoma	6.97e-05	0.000881	CcSEcCtD
Ponatinib—Pruritus—Thiotepa—sarcoma	6.95e-05	0.000877	CcSEcCtD
Ponatinib—Gastrointestinal pain—Mitoxantrone—sarcoma	6.93e-05	0.000876	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—sarcoma	6.92e-05	0.000874	CcSEcCtD
Ponatinib—Thrombocytopenia—Etoposide—sarcoma	6.9e-05	0.000872	CcSEcCtD
Ponatinib—Body temperature increased—Vincristine—sarcoma	6.88e-05	0.000869	CcSEcCtD
Ponatinib—Abdominal pain—Vincristine—sarcoma	6.88e-05	0.000869	CcSEcCtD
Ponatinib—ABCB1—embryo—sarcoma	6.87e-05	0.00112	CbGeAlD
Ponatinib—Skin disorder—Etoposide—sarcoma	6.85e-05	0.000865	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—sarcoma	6.82e-05	0.000862	CcSEcCtD
Ponatinib—ABCG2—testis—sarcoma	6.82e-05	0.00111	CbGeAlD
Ponatinib—Hyperhidrosis—Etoposide—sarcoma	6.82e-05	0.000861	CcSEcCtD
Ponatinib—Pancreatitis—Epirubicin—sarcoma	6.81e-05	0.000861	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—sarcoma	6.77e-05	0.000856	CcSEcCtD
Ponatinib—Angina pectoris—Epirubicin—sarcoma	6.77e-05	0.000855	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—sarcoma	6.72e-05	0.00085	CcSEcCtD
Ponatinib—Diarrhoea—Thiotepa—sarcoma	6.72e-05	0.000849	CcSEcCtD
Ponatinib—Body temperature increased—Mitoxantrone—sarcoma	6.7e-05	0.000847	CcSEcCtD
Ponatinib—Abdominal pain—Mitoxantrone—sarcoma	6.7e-05	0.000847	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	6.7e-05	0.000847	CcSEcCtD
Ponatinib—Diarrhoea—Dactinomycin—sarcoma	6.67e-05	0.000842	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—sarcoma	6.65e-05	0.000841	CcSEcCtD
Ponatinib—CYP2C8—liver—sarcoma	6.63e-05	0.00108	CbGeAlD
Ponatinib—Pancytopenia—Epirubicin—sarcoma	6.6e-05	0.000834	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	6.56e-05	0.000829	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—sarcoma	6.5e-05	0.000821	CcSEcCtD
Ponatinib—Dizziness—Thiotepa—sarcoma	6.49e-05	0.00082	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—sarcoma	6.47e-05	0.000818	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—sarcoma	6.46e-05	0.000816	CcSEcCtD
Ponatinib—ABCB1—seminal vesicle—sarcoma	6.46e-05	0.00105	CbGeAlD
Ponatinib—ABCG2—liver—sarcoma	6.45e-05	0.00105	CbGeAlD
Ponatinib—Paraesthesia—Etoposide—sarcoma	6.33e-05	0.0008	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—sarcoma	6.31e-05	0.000797	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—sarcoma	6.29e-05	0.000794	CcSEcCtD
Ponatinib—Dyspnoea—Etoposide—sarcoma	6.29e-05	0.000794	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—sarcoma	6.27e-05	0.000792	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—sarcoma	6.26e-05	0.000791	CcSEcCtD
Ponatinib—Asthenia—Vincristine—sarcoma	6.25e-05	0.000789	CcSEcCtD
Ponatinib—Vomiting—Thiotepa—sarcoma	6.24e-05	0.000789	CcSEcCtD
Ponatinib—Pneumonia—Epirubicin—sarcoma	6.23e-05	0.000788	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—sarcoma	6.2e-05	0.000783	CcSEcCtD
Ponatinib—Infestation—Epirubicin—sarcoma	6.2e-05	0.000783	CcSEcCtD
Ponatinib—Vomiting—Dactinomycin—sarcoma	6.19e-05	0.000783	CcSEcCtD
Ponatinib—Rash—Thiotepa—sarcoma	6.19e-05	0.000782	CcSEcCtD
Ponatinib—Dermatitis—Thiotepa—sarcoma	6.18e-05	0.000781	CcSEcCtD
Ponatinib—Headache—Thiotepa—sarcoma	6.15e-05	0.000777	CcSEcCtD
Ponatinib—Rash—Dactinomycin—sarcoma	6.14e-05	0.000776	CcSEcCtD
Ponatinib—ABCB1—hematopoietic system—sarcoma	6.14e-05	0.001	CbGeAlD
Ponatinib—Decreased appetite—Etoposide—sarcoma	6.13e-05	0.000774	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—sarcoma	6.11e-05	0.000772	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Etoposide—sarcoma	6.09e-05	0.000769	CcSEcCtD
Ponatinib—Asthenia—Mitoxantrone—sarcoma	6.08e-05	0.000768	CcSEcCtD
Ponatinib—Fatigue—Etoposide—sarcoma	6.08e-05	0.000768	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—sarcoma	6.07e-05	0.000767	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—sarcoma	6.04e-05	0.000763	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—sarcoma	6.04e-05	0.000763	CcSEcCtD
Ponatinib—Constipation—Etoposide—sarcoma	6.03e-05	0.000762	CcSEcCtD
Ponatinib—Pain—Etoposide—sarcoma	6.03e-05	0.000762	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—sarcoma	6.02e-05	0.000761	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—sarcoma	6.01e-05	0.00076	CcSEcCtD
Ponatinib—CYP3A5—liver—sarcoma	5.99e-05	0.000975	CbGeAlD
Ponatinib—Upper respiratory tract infection—Doxorubicin—sarcoma	5.98e-05	0.000755	CcSEcCtD
Ponatinib—Diarrhoea—Vincristine—sarcoma	5.96e-05	0.000752	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—sarcoma	5.86e-05	0.000741	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—sarcoma	5.85e-05	0.000739	CcSEcCtD
Ponatinib—Nausea—Thiotepa—sarcoma	5.83e-05	0.000737	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—sarcoma	5.82e-05	0.000735	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—sarcoma	5.8e-05	0.000733	CcSEcCtD
Ponatinib—Diarrhoea—Mitoxantrone—sarcoma	5.8e-05	0.000733	CcSEcCtD
Ponatinib—Nausea—Dactinomycin—sarcoma	5.79e-05	0.000731	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—sarcoma	5.77e-05	0.000729	CcSEcCtD
Ponatinib—Gastrointestinal pain—Etoposide—sarcoma	5.77e-05	0.000728	CcSEcCtD
Ponatinib—Dizziness—Vincristine—sarcoma	5.76e-05	0.000727	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—sarcoma	5.73e-05	0.000724	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—sarcoma	5.73e-05	0.000724	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—sarcoma	5.62e-05	0.00071	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—sarcoma	5.59e-05	0.000706	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—sarcoma	5.59e-05	0.000706	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—sarcoma	5.59e-05	0.000706	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—sarcoma	5.57e-05	0.000704	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—sarcoma	5.57e-05	0.000704	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—sarcoma	5.57e-05	0.000704	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—sarcoma	5.56e-05	0.000703	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—sarcoma	5.54e-05	0.000699	CcSEcCtD
Ponatinib—Vomiting—Vincristine—sarcoma	5.53e-05	0.000699	CcSEcCtD
Ponatinib—Rash—Vincristine—sarcoma	5.49e-05	0.000693	CcSEcCtD
Ponatinib—Dermatitis—Vincristine—sarcoma	5.48e-05	0.000693	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—sarcoma	5.48e-05	0.000692	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—sarcoma	5.47e-05	0.000691	CcSEcCtD
Ponatinib—Headache—Vincristine—sarcoma	5.45e-05	0.000689	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—sarcoma	5.42e-05	0.000685	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—sarcoma	5.41e-05	0.000683	CcSEcCtD
Ponatinib—Vomiting—Mitoxantrone—sarcoma	5.39e-05	0.000681	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—sarcoma	5.36e-05	0.000677	CcSEcCtD
Ponatinib—Rash—Mitoxantrone—sarcoma	5.34e-05	0.000675	CcSEcCtD
Ponatinib—Dermatitis—Mitoxantrone—sarcoma	5.34e-05	0.000675	CcSEcCtD
Ponatinib—Headache—Mitoxantrone—sarcoma	5.31e-05	0.000671	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—sarcoma	5.2e-05	0.000657	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—sarcoma	5.17e-05	0.000654	CcSEcCtD
Ponatinib—Nausea—Vincristine—sarcoma	5.17e-05	0.000653	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—sarcoma	5.16e-05	0.000652	CcSEcCtD
Ponatinib—Flushing—Epirubicin—sarcoma	5.16e-05	0.000652	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—sarcoma	5.15e-05	0.00065	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—sarcoma	5.12e-05	0.000647	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—sarcoma	5.07e-05	0.000641	CcSEcCtD
Ponatinib—Asthenia—Etoposide—sarcoma	5.06e-05	0.000639	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—sarcoma	5.06e-05	0.000639	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—sarcoma	5.05e-05	0.000638	CcSEcCtD
Ponatinib—Nausea—Mitoxantrone—sarcoma	5.04e-05	0.000636	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—sarcoma	5.01e-05	0.000633	CcSEcCtD
Ponatinib—Chills—Epirubicin—sarcoma	4.99e-05	0.000631	CcSEcCtD
Ponatinib—Pruritus—Etoposide—sarcoma	4.99e-05	0.00063	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—sarcoma	4.97e-05	0.000628	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—sarcoma	4.96e-05	0.000627	CcSEcCtD
Ponatinib—ABCG2—lymph node—sarcoma	4.94e-05	0.000805	CbGeAlD
Ponatinib—Alopecia—Epirubicin—sarcoma	4.92e-05	0.000621	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—sarcoma	4.87e-05	0.000616	CcSEcCtD
Ponatinib—Erythema—Epirubicin—sarcoma	4.84e-05	0.000612	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—sarcoma	4.84e-05	0.000612	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—sarcoma	4.82e-05	0.00061	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—sarcoma	4.81e-05	0.000608	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—sarcoma	4.78e-05	0.000604	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—sarcoma	4.78e-05	0.000604	CcSEcCtD
Ponatinib—Back pain—Epirubicin—sarcoma	4.68e-05	0.000592	CcSEcCtD
Ponatinib—CYP2D6—testis—sarcoma	4.68e-05	0.000762	CbGeAlD
Ponatinib—Angiopathy—Doxorubicin—sarcoma	4.67e-05	0.00059	CcSEcCtD
Ponatinib—Dizziness—Etoposide—sarcoma	4.66e-05	0.000589	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—sarcoma	4.66e-05	0.000588	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—sarcoma	4.64e-05	0.000586	CcSEcCtD
Ponatinib—ABCB1—uterus—sarcoma	4.64e-05	0.000755	CbGeAlD
Ponatinib—Chills—Doxorubicin—sarcoma	4.62e-05	0.000584	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—sarcoma	4.6e-05	0.000581	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—sarcoma	4.56e-05	0.000577	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—sarcoma	4.55e-05	0.000575	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—sarcoma	4.51e-05	0.00057	CcSEcCtD
Ponatinib—CYP3A4—liver—sarcoma	4.49e-05	0.000732	CbGeAlD
Ponatinib—Vomiting—Etoposide—sarcoma	4.48e-05	0.000566	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—sarcoma	4.48e-05	0.000566	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—sarcoma	4.48e-05	0.000566	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—sarcoma	4.48e-05	0.000566	CcSEcCtD
Ponatinib—Rash—Etoposide—sarcoma	4.45e-05	0.000562	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—sarcoma	4.44e-05	0.000561	CcSEcCtD
Ponatinib—CYP2D6—liver—sarcoma	4.42e-05	0.00072	CbGeAlD
Ponatinib—Headache—Etoposide—sarcoma	4.42e-05	0.000558	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—sarcoma	4.34e-05	0.000548	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—sarcoma	4.33e-05	0.000548	CcSEcCtD
Ponatinib—ABCB1—lymphoid tissue—sarcoma	4.32e-05	0.000704	CbGeAlD
Ponatinib—Muscle spasms—Doxorubicin—sarcoma	4.31e-05	0.000544	CcSEcCtD
Ponatinib—Cough—Epirubicin—sarcoma	4.23e-05	0.000534	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—sarcoma	4.22e-05	0.000534	CcSEcCtD
Ponatinib—Nausea—Etoposide—sarcoma	4.19e-05	0.000529	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—sarcoma	4.18e-05	0.000528	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—sarcoma	4.14e-05	0.000523	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—sarcoma	4.12e-05	0.000521	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—sarcoma	4.12e-05	0.000521	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	4.09e-05	0.000517	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—sarcoma	4.03e-05	0.000509	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—sarcoma	4.01e-05	0.000507	CcSEcCtD
Ponatinib—Oedema—Epirubicin—sarcoma	3.95e-05	0.000499	CcSEcCtD
Ponatinib—ABCB1—bone marrow—sarcoma	3.93e-05	0.000641	CbGeAlD
Ponatinib—Infection—Epirubicin—sarcoma	3.93e-05	0.000496	CcSEcCtD
Ponatinib—Cough—Doxorubicin—sarcoma	3.91e-05	0.000494	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—sarcoma	3.88e-05	0.00049	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—sarcoma	3.87e-05	0.000489	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—sarcoma	3.87e-05	0.000489	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—sarcoma	3.84e-05	0.000485	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—sarcoma	3.82e-05	0.000483	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—sarcoma	3.82e-05	0.000482	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—sarcoma	3.82e-05	0.000482	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	3.79e-05	0.000479	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—sarcoma	3.73e-05	0.000471	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—sarcoma	3.66e-05	0.000462	CcSEcCtD
Ponatinib—Infection—Doxorubicin—sarcoma	3.63e-05	0.000459	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—sarcoma	3.6e-05	0.000455	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—sarcoma	3.59e-05	0.000453	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—sarcoma	3.58e-05	0.000452	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—sarcoma	3.57e-05	0.000452	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—sarcoma	3.55e-05	0.000449	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—sarcoma	3.55e-05	0.000448	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—sarcoma	3.54e-05	0.000447	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—sarcoma	3.52e-05	0.000445	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—sarcoma	3.48e-05	0.00044	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—sarcoma	3.44e-05	0.000434	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—sarcoma	3.41e-05	0.000431	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—sarcoma	3.41e-05	0.000431	CcSEcCtD
Ponatinib—Constipation—Epirubicin—sarcoma	3.38e-05	0.000427	CcSEcCtD
Ponatinib—Pain—Epirubicin—sarcoma	3.38e-05	0.000427	CcSEcCtD
Ponatinib—ABCB1—testis—sarcoma	3.36e-05	0.000548	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—sarcoma	3.33e-05	0.000421	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—sarcoma	3.31e-05	0.000418	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—sarcoma	3.28e-05	0.000415	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—sarcoma	3.26e-05	0.000412	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—sarcoma	3.23e-05	0.000408	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—sarcoma	3.22e-05	0.000407	CcSEcCtD
Ponatinib—ABCB1—liver—sarcoma	3.18e-05	0.000518	CbGeAlD
Ponatinib—Decreased appetite—Doxorubicin—sarcoma	3.18e-05	0.000402	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—sarcoma	3.16e-05	0.000399	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—sarcoma	3.15e-05	0.000398	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—sarcoma	3.13e-05	0.000395	CcSEcCtD
Ponatinib—Pain—Doxorubicin—sarcoma	3.13e-05	0.000395	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—sarcoma	3.12e-05	0.000395	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—sarcoma	3.12e-05	0.000395	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—sarcoma	2.99e-05	0.000378	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—sarcoma	2.89e-05	0.000365	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—sarcoma	2.89e-05	0.000365	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—sarcoma	2.84e-05	0.000358	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—sarcoma	2.8e-05	0.000353	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—sarcoma	2.7e-05	0.000342	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—sarcoma	2.62e-05	0.000332	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—sarcoma	2.61e-05	0.00033	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—sarcoma	2.59e-05	0.000327	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—sarcoma	2.51e-05	0.000318	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—sarcoma	2.5e-05	0.000316	CcSEcCtD
Ponatinib—Rash—Epirubicin—sarcoma	2.49e-05	0.000315	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—sarcoma	2.49e-05	0.000315	CcSEcCtD
Ponatinib—Headache—Epirubicin—sarcoma	2.48e-05	0.000313	CcSEcCtD
Ponatinib—ABCB1—lymph node—sarcoma	2.44e-05	0.000397	CbGeAlD
Ponatinib—Dizziness—Doxorubicin—sarcoma	2.42e-05	0.000306	CcSEcCtD
Ponatinib—Nausea—Epirubicin—sarcoma	2.35e-05	0.000297	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—sarcoma	2.33e-05	0.000294	CcSEcCtD
Ponatinib—Rash—Doxorubicin—sarcoma	2.31e-05	0.000291	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—sarcoma	2.3e-05	0.000291	CcSEcCtD
Ponatinib—Headache—Doxorubicin—sarcoma	2.29e-05	0.000289	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—sarcoma	2.17e-05	0.000274	CcSEcCtD
Ponatinib—FGFR1—Disease—CTNNB1—sarcoma	2.68e-06	2.36e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HRAS—sarcoma	2.67e-06	2.36e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CTNNB1—sarcoma	2.67e-06	2.36e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—NRAS—sarcoma	2.65e-06	2.34e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—HRAS—sarcoma	2.65e-06	2.34e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—NRAS—sarcoma	2.65e-06	2.34e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—sarcoma	2.65e-06	2.34e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PLCG1—sarcoma	2.64e-06	2.33e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—SRC—sarcoma	2.64e-06	2.33e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL2—sarcoma	2.64e-06	2.33e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—KRAS—sarcoma	2.64e-06	2.33e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL2—sarcoma	2.64e-06	2.33e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KDR—sarcoma	2.63e-06	2.33e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL2—sarcoma	2.63e-06	2.32e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—sarcoma	2.63e-06	2.32e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CREB1—sarcoma	2.63e-06	2.32e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—SRC—sarcoma	2.62e-06	2.31e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CREB1—sarcoma	2.62e-06	2.31e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—SRC—sarcoma	2.61e-06	2.31e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FOXO1—sarcoma	2.61e-06	2.3e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PDGFRB—sarcoma	2.61e-06	2.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—SRC—sarcoma	2.59e-06	2.29e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CREB1—sarcoma	2.59e-06	2.29e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KRAS—sarcoma	2.58e-06	2.28e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VEGFA—sarcoma	2.57e-06	2.27e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CCND1—sarcoma	2.57e-06	2.27e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—JUN—sarcoma	2.57e-06	2.27e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—JUN—sarcoma	2.57e-06	2.27e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PDGFRA—sarcoma	2.56e-06	2.26e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ENO2—sarcoma	2.56e-06	2.26e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—JUN—sarcoma	2.56e-06	2.26e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—CTNNB1—sarcoma	2.55e-06	2.25e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—SRC—sarcoma	2.55e-06	2.25e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CTNNB1—sarcoma	2.55e-06	2.25e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HBA1—sarcoma	2.54e-06	2.25e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NRAS—sarcoma	2.54e-06	2.24e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CTNNB1—sarcoma	2.54e-06	2.24e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—HRAS—sarcoma	2.54e-06	2.24e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—NRAS—sarcoma	2.52e-06	2.22e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—EGFR—sarcoma	2.52e-06	2.22e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KIT—sarcoma	2.51e-06	2.22e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—HRAS—sarcoma	2.51e-06	2.22e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—NRAS—sarcoma	2.51e-06	2.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—NRAS—sarcoma	2.5e-06	2.2e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—EGFR—sarcoma	2.46e-06	2.17e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—NRAS—sarcoma	2.45e-06	2.16e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1R—sarcoma	2.43e-06	2.14e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KIT—sarcoma	2.43e-06	2.14e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MDM2—sarcoma	2.42e-06	2.14e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—EGFR—sarcoma	2.42e-06	2.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—SRC—sarcoma	2.42e-06	2.14e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—EGFR—sarcoma	2.42e-06	2.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—SRC—sarcoma	2.41e-06	2.13e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CREB1—sarcoma	2.39e-06	2.11e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KRAS—sarcoma	2.38e-06	2.1e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MYC—sarcoma	2.37e-06	2.09e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—sarcoma	2.35e-06	2.07e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MDM2—sarcoma	2.33e-06	2.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KRAS—sarcoma	2.33e-06	2.05e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—NRAS—sarcoma	2.33e-06	2.05e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MYC—sarcoma	2.32e-06	2.05e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—NRAS—sarcoma	2.32e-06	2.05e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—EGFR—sarcoma	2.32e-06	2.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FOXO1—sarcoma	2.31e-06	2.04e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CREB1—sarcoma	2.31e-06	2.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PDGFRB—sarcoma	2.31e-06	2.04e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—SRC—sarcoma	2.3e-06	2.03e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PLCG1—sarcoma	2.3e-06	2.03e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—SRC—sarcoma	2.3e-06	2.03e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—EGFR—sarcoma	2.3e-06	2.03e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—SRC—sarcoma	2.29e-06	2.02e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—EGFR—sarcoma	2.29e-06	2.02e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MDM2—sarcoma	2.29e-06	2.02e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—HRAS—sarcoma	2.29e-06	2.02e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—KRAS—sarcoma	2.29e-06	2.02e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MYC—sarcoma	2.28e-06	2.02e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KRAS—sarcoma	2.28e-06	2.02e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—HRAS—sarcoma	2.28e-06	2.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—EGFR—sarcoma	2.27e-06	2.01e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PDGFRA—sarcoma	2.27e-06	2e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—HRAS—sarcoma	2.24e-06	1.98e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—sarcoma	2.24e-06	1.98e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MDM2—sarcoma	2.24e-06	1.97e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—EGFR—sarcoma	2.23e-06	1.97e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—NRAS—sarcoma	2.22e-06	1.96e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NRAS—sarcoma	2.21e-06	1.95e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NRAS—sarcoma	2.21e-06	1.95e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—sarcoma	2.19e-06	1.93e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KRAS—sarcoma	2.19e-06	1.93e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MDM2—sarcoma	2.17e-06	1.92e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PLCG1—sarcoma	2.17e-06	1.92e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KRAS—sarcoma	2.17e-06	1.91e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MYC—sarcoma	2.17e-06	1.91e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MDM2—sarcoma	2.17e-06	1.91e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL2—sarcoma	2.16e-06	1.91e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KRAS—sarcoma	2.16e-06	1.91e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MYC—sarcoma	2.16e-06	1.91e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KDR—sarcoma	2.16e-06	1.91e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KRAS—sarcoma	2.15e-06	1.9e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MDM2—sarcoma	2.14e-06	1.89e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EGFR—sarcoma	2.12e-06	1.87e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EGFR—sarcoma	2.11e-06	1.87e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—KRAS—sarcoma	2.11e-06	1.86e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—JUN—sarcoma	2.11e-06	1.86e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CTNNB1—sarcoma	2.09e-06	1.84e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—sarcoma	2.08e-06	1.84e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MYC—sarcoma	2.06e-06	1.82e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—sarcoma	2.04e-06	1.81e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCND1—sarcoma	2.03e-06	1.79e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—JUN—sarcoma	2.03e-06	1.79e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—sarcoma	2.02e-06	1.78e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EGFR—sarcoma	2.02e-06	1.78e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EGFR—sarcoma	2.02e-06	1.78e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EGFR—sarcoma	2.01e-06	1.77e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CTNNB1—sarcoma	2.01e-06	1.77e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KRAS—sarcoma	2e-06	1.77e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—sarcoma	2e-06	1.76e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCND1—sarcoma	1.99e-06	1.76e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—JUN—sarcoma	1.99e-06	1.76e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KIT—sarcoma	1.99e-06	1.76e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MDM2—sarcoma	1.98e-06	1.75e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—sarcoma	1.98e-06	1.75e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CTNNB1—sarcoma	1.97e-06	1.74e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—sarcoma	1.94e-06	1.72e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—sarcoma	1.94e-06	1.71e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—sarcoma	1.94e-06	1.71e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—sarcoma	1.94e-06	1.71e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—sarcoma	1.94e-06	1.71e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CTNNB1—sarcoma	1.93e-06	1.7e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—sarcoma	1.92e-06	1.69e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KDR—sarcoma	1.91e-06	1.69e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MDM2—sarcoma	1.91e-06	1.69e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—sarcoma	1.91e-06	1.68e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—sarcoma	1.91e-06	1.68e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—sarcoma	1.9e-06	1.68e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CREB1—sarcoma	1.89e-06	1.67e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCND1—sarcoma	1.89e-06	1.67e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—SRC—sarcoma	1.89e-06	1.67e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—JUN—sarcoma	1.89e-06	1.67e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—sarcoma	1.89e-06	1.67e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—JUN—sarcoma	1.88e-06	1.66e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CTNNB1—sarcoma	1.87e-06	1.65e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CTNNB1—sarcoma	1.87e-06	1.65e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—JUN—sarcoma	1.86e-06	1.65e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—sarcoma	1.86e-06	1.64e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CTNNB1—sarcoma	1.85e-06	1.63e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—sarcoma	1.84e-06	1.63e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—sarcoma	1.84e-06	1.62e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—sarcoma	1.83e-06	1.61e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NRAS—sarcoma	1.82e-06	1.6e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SRC—sarcoma	1.82e-06	1.6e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—sarcoma	1.79e-06	1.58e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SRC—sarcoma	1.78e-06	1.58e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—sarcoma	1.77e-06	1.56e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KIT—sarcoma	1.76e-06	1.55e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—sarcoma	1.75e-06	1.54e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—SRC—sarcoma	1.74e-06	1.54e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—sarcoma	1.74e-06	1.53e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—sarcoma	1.72e-06	1.52e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CTNNB1—sarcoma	1.71e-06	1.51e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—sarcoma	1.71e-06	1.51e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—sarcoma	1.7e-06	1.5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—sarcoma	1.7e-06	1.5e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—sarcoma	1.69e-06	1.5e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SRC—sarcoma	1.69e-06	1.5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SRC—sarcoma	1.69e-06	1.49e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—sarcoma	1.68e-06	1.48e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CREB1—sarcoma	1.68e-06	1.48e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO2—sarcoma	1.67e-06	1.48e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—sarcoma	1.66e-06	1.47e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HBA1—sarcoma	1.66e-06	1.47e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—JUN—sarcoma	1.66e-06	1.47e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—sarcoma	1.66e-06	1.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—sarcoma	1.65e-06	1.46e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CTNNB1—sarcoma	1.65e-06	1.46e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—sarcoma	1.65e-06	1.45e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—sarcoma	1.63e-06	1.44e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—sarcoma	1.63e-06	1.44e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—sarcoma	1.62e-06	1.43e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—sarcoma	1.62e-06	1.43e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—sarcoma	1.62e-06	1.43e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—sarcoma	1.61e-06	1.43e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—sarcoma	1.61e-06	1.42e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—sarcoma	1.6e-06	1.41e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—sarcoma	1.59e-06	1.41e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MDM2—sarcoma	1.57e-06	1.38e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—sarcoma	1.56e-06	1.38e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—sarcoma	1.56e-06	1.38e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—sarcoma	1.56e-06	1.38e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—sarcoma	1.53e-06	1.35e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—sarcoma	1.52e-06	1.34e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—sarcoma	1.51e-06	1.34e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—sarcoma	1.5e-06	1.33e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SRC—sarcoma	1.49e-06	1.32e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—sarcoma	1.49e-06	1.31e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—sarcoma	1.48e-06	1.31e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—sarcoma	1.48e-06	1.31e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—sarcoma	1.48e-06	1.3e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—sarcoma	1.47e-06	1.29e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—sarcoma	1.45e-06	1.28e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—sarcoma	1.44e-06	1.27e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—sarcoma	1.43e-06	1.27e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PLCG1—sarcoma	1.42e-06	1.25e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—sarcoma	1.4e-06	1.24e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—sarcoma	1.4e-06	1.24e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—sarcoma	1.4e-06	1.23e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MDM2—sarcoma	1.39e-06	1.22e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—sarcoma	1.38e-06	1.22e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—sarcoma	1.38e-06	1.22e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—sarcoma	1.36e-06	1.2e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JUN—sarcoma	1.36e-06	1.2e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—sarcoma	1.35e-06	1.19e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—sarcoma	1.35e-06	1.19e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—sarcoma	1.34e-06	1.18e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—sarcoma	1.34e-06	1.18e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—sarcoma	1.33e-06	1.17e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—sarcoma	1.31e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—sarcoma	1.31e-06	1.15e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—sarcoma	1.28e-06	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—sarcoma	1.28e-06	1.13e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—sarcoma	1.26e-06	1.11e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—sarcoma	1.25e-06	1.1e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—sarcoma	1.24e-06	1.1e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—sarcoma	1.24e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—sarcoma	1.23e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—sarcoma	1.23e-06	1.08e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SRC—sarcoma	1.22e-06	1.08e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—sarcoma	1.21e-06	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JUN—sarcoma	1.21e-06	1.06e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—sarcoma	1.2e-06	1.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—sarcoma	1.19e-06	1.05e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—sarcoma	1.19e-06	1.05e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—sarcoma	1.19e-06	1.05e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—sarcoma	1.18e-06	1.04e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—sarcoma	1.17e-06	1.04e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—sarcoma	1.1e-06	9.68e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—sarcoma	1.09e-06	9.66e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—sarcoma	1.09e-06	9.59e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—sarcoma	1.07e-06	9.45e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—sarcoma	1.05e-06	9.3e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—sarcoma	1.05e-06	9.26e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—sarcoma	1.04e-06	9.18e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—sarcoma	1.01e-06	8.93e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—sarcoma	9.69e-07	8.55e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—sarcoma	9.48e-07	8.37e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—sarcoma	8.99e-07	7.93e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—sarcoma	8.95e-07	7.9e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—sarcoma	8.59e-07	7.59e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—sarcoma	7.96e-07	7.02e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—sarcoma	7.61e-07	6.72e-06	CbGpPWpGaD
